CDD for Biologics

Memo

Returning 13-15 November, the 3rd Annual meeting remains the only industry-centric meeting solely dedicated to exploring the in silico prediction, design, and modelling of biotherapeutics. Across 3 days of intensive presentations, discussion and debate, the event will again unite computational leaders from pioneering pharmaceutical organizations, academic and software development labs. This year, topics will span the in silico prediction, design, and modelling of biologics. With a greater focus beyond applications limited to MAb’s the agenda will showcase advances with computational tools for vaccine, enzyme, multispecific and linker-based biologics and highlight the iterative experimental processes. The CDD for Biologics Summit remains solely dedicated to exploring the power of in silico tools to de-risk biologics drug development. Our mission has been, and remains, to provide a forum that unite stakeholders from across pharma, academia and software providers along with the end users in computational biology, structural biology and bioinformatics to define current capabilities, and realise how these tools can be further adapted to add immediate value to biologics pipelines. Focused principally on design and developability of antibodies, this year’s case studies will reveal the applications of these methods to other biotherapeutic modalities, from early drug discovery through to late preclinical development. Discussion will centre around means to overcome data availability, model validation and standardization issues. Join us to identify market trends, enhance cost-effectiveness, shorten biologics development timelines and accelerate program development with insights from our industry leading speaker faculty. Visit cdd-biologics.com to find out more and download the full event brochure here: cdd-biologics.com/agenda/full-event-guide/  Prices:Gold Package: Conference + Full Day Workshops: USD 3699.0Bronze Package: Conference Only: USD 2699.0Full Day Workshop Only: USD 1399.0 Speakers: Bojana Popovic, Principal Scientist - Antibody Discovery and Protein Engineering, MedImmune Protein Engineering, MedImmune, Rafael Depetris, Principal Scientist, Kadmon Corporation, Jacob Glanville, Co-Founder and Chief Science Officer, Distributed Bio, Dana Fioti, Senior Scientist, AbbVie, Alex Jacobitz, Process Development Scientist, Amgen, Antonios Samiotakis, Principal Scientist, Technology Integration and Bioinformatics, Zymeworks Inc, Alexandre Zanghellini, CEO and VP Research, Arzeda Corp, Benjamin Walters, Scientist, Genentech, Chris Roberts, Professor of Chemical and Biomolecular Engineering, University of Delaware, Christopher D. Bahl, Head of Protein Design, Institute for Protein Innovation, Enrico O. Purisima, Molecular Modeling Team Leader, National Research Council Canada, Human Health Therapeutics Research Centre, Gwo-Yu Chuang, Staff Scientist and Co-head, Structural Bioinformatics Core Section, Vaccine Research Center, NIAID/NIH, Jeffrey Grey, Professor Chemical and Biomolecular Engineering, Johns Hopkins University School of Medicine, Jeffrey Way, Senior Staff Scientist, Wyss Institute, Harvard University, Jeremy Shaver, Principal Scientist, Data Science, Just Biotherapeutics, Jerome Baudry, Pei-Ling Chan Eminent Scholar and Professor, University Of Alabama In Huntsville, Jonathan Zarzar, Engineer II, Genentech, Krishna Praneeth, Kilambi Scientist, Biogen, Neeraj Agrawal, Senior Scientist, Process Development, Amgen, Nic Angell, Director Process Development, Amgen, Norbert Furtmann, Lab Head Bioinformatics, High Throughput Biologics, RandD Biologics Research/Protein Therapeutics, Sanofi-Aventis, Roland Dunbrack, Professor, Fox Chase Cancer Center, Sagar Khare, Associate Professor, Rutgers University Time: 7:30 am - 4:00 pm